receptor for advanced glycation end products

Overview

The receptor for advanced glycation end products (RAGE) is a multiligand pattern-recognition receptor belonging to the immunoglobulin superfamily of cell surface proteins. Encoded by the AGER gene, RAGE is expressed on a broad range of cell types including endothelial cells, smooth muscle cells, neurons, microglia, osteoclasts, chondrocytes, and immune cells. Its primary ligands include advanced glycation end products (AGEs)—stable adducts formed by non-enzymatic glycation of proteins and lipids under conditions of chronic hyperglycemia or oxidative stress—as well as damage-associated molecular patterns (DAMPs) such as high mobility group box 1 protein (HMGB1) and members of the S100 protein family. Upon ligand engagement, RAGE activates downstream signaling cascades most prominently involving NF-κB, MAPK, and Rho GTPase effectors, driving sustained inflammatory gene expression, oxidative stress, and cellular dysfunction.

RAGE occupies a central node at the intersection of metabolic disease, sterile inflammation, aging, and cancer biology. Because its activation is perpetuated rather than resolved by continued ligand availability—a self-amplifying loop characteristic of chronic disease states—RAGE has attracted considerable interest as a therapeutic target. Its cytoplasmic tail interacts with the formin homology protein diaphanous-1 (DIAPH1), an interaction required for intracellular signal transduction, and extracellular engagement is further modulated by co-receptors including TLR4, establishing RAGE as a hub integrating multiple danger-sensing pathways.

Focus of Latest Publications

Recent publications highlight RAGE's involvement across a remarkably diverse set of pathologies, underscoring its status as a convergent mediator of inflammation and tissue injury.

Aging and breast cancer metastasis. A 2026 study published in Communications Biology demonstrated that aging markedly increases breast cancer metastasis across multiple mouse models and that this pro-metastatic effect is dependent on host expression of RAGE. The findings position RAGE not merely as an intracellular mediator within tumor cells, but as a host-tissue factor whose age-associated upregulation remodels the microenvironment to favor tumor dissemination. This work integrates RAGE biology with transcriptional programs governing angiogenesis, epithelial-to-mesenchymal transition (EMT), extracellular matrix remodeling, and inflammation—gene programs that collectively facilitate metastatic seeding and colonization.

Acute hyperglycemia, NETosis, and ischemic stroke. Research published in the European Journal of Pharmacology in 2026 identified the RAGE/DIAPH1 signaling axis as a mechanistic driver of neutrophil extracellular trap (NET) formation (NETosis) and futile recanalization following ischemic stroke under conditions of acute hyperglycemia. The study illuminates how episodic glycemic spikes—not merely chronic hyperglycemia—can engage RAGE to amplify neurovascular injury, suggesting that acute metabolic perturbations carry distinct signaling consequences through this receptor.

Neuroinflammation and alarmin signaling. A study in ACS Chemical Neuroscience examining dendritic polyglycerol nanostructures and their effects on interleukin-33 signaling in spinal cord microglia specifically identified heparan sulfate interaction with HMGB1 as critical for RAGE-mediated signaling. This work connects RAGE to the broader alarmin network, wherein HMGB1 released from damaged or activated cells engages RAGE to sustain neuroinflammatory cascades—a mechanism of relevance to neuroimmune disorders and central nervous system injury.

Osteoarthritis and chondrocyte senescence. In a 2026 Aging Cell study employing an OA mouse model, AGE-RAGE signaling was shown to suppress SIRT1 expression, activate RANKL-dependent osteoclast signaling, and drive chondrocyte senescence during osteoarthritis development. Pharmacological inhibition of RAGE or shRNA-mediated gene silencing of the receptor restored SIRT1 levels, confirming RAGE's upstream role in this pathological cascade. These results integrate RAGE into the senescence and epigenetic dysregulation that characterizes aging joints.

Diabetic kidney disease and the AGE-RAGE-NF-κB axis. A medicinal chemistry study published in Biochemical and Biophysical Research Communications described the discovery of SBLR876, a potent small-molecule RAGE inhibitor. The study framed diabetic kidney disease pathogenesis around the AGE-RAGE-NF-κB axis—wherein sustained RAGE activation by AGEs drives cytotoxicity and proinflammatory cytokine production, contributing to glomerular and tubular injury. SBLR876 was identified as capable of mitigating these downstream effects, providing a candidate therapeutic scaffold for diabetic nephropathy.

Metabolic dysfunction-associated steatotic liver disease (MASLD). A study in the Journal of Clinical and Experimental Hepatology investigated the association between genetic polymorphism in RAGE and metabolic dysfunction-associated steatotic liver disease (also referred to as metabolic dysfunction-associated steatohepatitis, MASH). The findings suggest that AGEs and RAGE may contribute to MASLD development and progression, extending the receptor's pathological footprint to the liver and metabolic syndrome. The specific single-nucleotide polymorphism examined (rs1800624) links common genetic variation in AGER to disease susceptibility.

Key Publications

May Dually Charged Dendrimeric Polyglycerol Modulates Interleukin-33 at Alarmin Receptors in Microglia. (ACS chemical neuroscience, 2026, PMID 42081615): "...heparan sulfate interaction with the alarmin high mobility group box 1 (HMGB1) is critical for receptor for advanced glycation end products (RAGE)-mediated signaling."
May Aging promotes a RAGE-dependent increase in breast cancer metastasis. (Communications biology, 2026, PMID 42141167): "Here, we show that aging markedly increases breast cancer metastasis in multiple mouse models, and this effect is dependent on host expression of the Receptor for Advanced Glycation End-products (RAGE)."
May Acute hyperglycemia induces NETosis and futile recanalization after ischemic stroke via RAGE/DIAPH1 pathway. (European journal of pharmacology, 2026, PMID 41990906): "...via the receptor for advanced glycation end products (RAGE)/diaphanous-1 (DIAPH1) signaling axis..."
May SIRT1 Downregulation by Advanced Glycation End Products Activates RANKL-Dependent Osteoclast Signaling and Drives Chondrocyte Senescence During Osteoarthritis Development. (Aging cell, 2026, PMID 42067949): "Pharmacological inhibition of RAGE or shRNA-mediated gene silencing restored SIRT1 expression, confirming the upstream role of AGE-RAGE signaling."
May The Association Between Genetic Polymorphism in the Receptor for Advanced Glycation End-Products and Metabolic Dysfunction-Associated Steatotic Liver Disease. (Journal of clinical and experimental hepatology, 2026, PMID 41908674): "AGEs and the receptor for AGEs (RAGE) might be involved in MASLD development and progression."
May Integrated discovery of SBLR876: a potent RAGE inhibitor mitigating AGE-RAGE-NF-κB-mediated cytotoxicity and inflammation in diabetic kidney disease. (Biochemical and biophysical research communications, 2026, PMID 41825171): "The receptor for advanced glycation end products (RAGE) drives these processes via the AGE-RAGE-NF-κB axis."